MCK vs. COR, CAH, HSIC, PDCO, OMI, HLF, PETQ, NUS, COSM, and MEDS
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), PetIQ (PETQ), Nu Skin Enterprises (NUS), Cosmos Health (COSM), and TRxADE HEALTH (MEDS).
McKesson (NYSE:MCK) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.4%. Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays out 11.1% of its earnings in the form of a dividend. Cencora pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
85.1% of McKesson shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 0.1% of McKesson shares are held by company insiders. Comparatively, 15.8% of Cencora shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
McKesson has a net margin of 0.97% compared to Cencora's net margin of 0.67%. Cencora's return on equity of 268.67% beat McKesson's return on equity.
McKesson presently has a consensus target price of $599.33, suggesting a potential downside of 0.14%. Cencora has a consensus target price of $238.78, suggesting a potential upside of 4.92%. Given Cencora's higher possible upside, analysts clearly believe Cencora is more favorable than McKesson.
McKesson has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
McKesson received 221 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.34% of users gave McKesson an outperform vote while only 65.18% of users gave Cencora an outperform vote.
McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cencora had 3 more articles in the media than McKesson. MarketBeat recorded 20 mentions for Cencora and 17 mentions for McKesson. McKesson's average media sentiment score of 0.62 beat Cencora's score of 0.50 indicating that McKesson is being referred to more favorably in the media.
Summary
McKesson beats Cencora on 12 of the 19 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
